Tyra Biosciences (TYRA) announced that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib is a potential first-in-class, once-daily oral FGFR3 selective inhibitor that was discovered using the TYRA’s in-house SNAP platform.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Bioscience: Strategic Advancements and Financial Stability Justify Buy Rating
- Tyra Bioscience: Promising Clinical Trials and Financial Stability Justify Buy Rating
- Tyra Biosciences Advances Clinical Programs with Strong Financial Backing
- Tyra Biosciences reports Q2 EPS (47c), consensus (51c)
- Tyra Biosciences announces presentation on TYRA-300 preclinical results at ENDO